WEDNESDAY, Sept. 5 (HealthDay News) -- Bosulif (bosutinib) has been approved by the U.S. Food and Drug Administration to treat chronic myelogenous leukemia (CML), the agency said in a news release.
Bosulif is intended for patients with chronic, accelerated or blast phase Philadelphia chromosome positive CML who are resistant to or who cannot tolerate other therapies, including imatinib, the FDA said. Bosulif works by blocking the tyrosine kinase signal that promotes abnormal, unhealthy granulocyte development.
Bosulif was evaluated in a clinical trial that included 546 adults with CML. The drug's most common side effects included diarrhea, nausea, thrombocytopenia, abdominal pain, rash, anemia, fever, and fatigue.
The drug is marketed by Pfizer, based in New York City.
To learn more about this approval, visit the FDA.
Copyright © 2012 HealthDay. All rights reserved.
|Previous: World Cancer Congress, Aug. 27-30, 2012||Next: Less Pain After Hysterectomy With Vessel Sealing|
Reader comments on this article are listed below. Review our comments policy.
Submit your opinion:
Are you a Doctor, Pharmacist, PA or a Nurse?
Join the Doctors Lounge online medical community